Stop mapping the pharma customer journey and start responding to it

Stop mapping the pharma customer journey and start responding to it

Stop mapping the pharma customer journey and start responding to it

Somewhere in our industry right now, somebody is drawing a beautifully orchestrated customer journey on a PowerPoint slide, complete with a personalised message for every brand touchpoint. The real journey, unfortunately, is never quite that tidy and it is becoming less predictable by the minute. The patient is asking ChatGPT for advice, the HCP is getting AI-driven recommendations directly in their clinical workflow and neither is especially concerned about the map your brand expects them to follow.

This scenario creates an urgent mandate for pharma marketing. The decision environment is changing rapidly but this disruption offers a remarkable opportunity to reimagine growth. Brands must shift from predetermined messaging to context-responsive engagement to truly add value in this redrawn landscape of influence.

The AI-driven decision environment

The way people reach health decisions is changing and AI is the primary catalyst. A new decision environment has emerged where large language models (LLMs) increasingly help patients and HCPs interpret information, narrow their options and decide what to do next. For HCPs, AI-led guidance is rapidly becoming part of the clinical workflow. Health technology companies are actively deploying tools that bring evidence and individual patient context together to support clinical decisions, delivering recommendations directly through the EHR at the point of care.

Physicians are already acting on this AI-generated guidance. In one large-scale study of UTI management that began back in 2021 – when comfort with AI was still nascent – physicians followed an AI-driven treatment recommendation in 66% of cases. When they did, ciprofloxacin prescribing was 80.5% lower than when they rejected the recommendation. This represents a massive and undeniable shift in clinical behaviour.*

For healthcare marketers, this means simply being visible across traditional touchpoints is no longer enough. Brands must proactively ensure their clinical evidence is structured and surfaced so that it shapes AI-led guidance, or they risk missing the most crucial moments of influence.

From predetermined to context-responsive engagement

A more dynamic decision environment requires brands to think differently about how they engage. Pharma has traditionally mapped customer journeys, planned touchpoints and developed messages designed to influence what happens along the way. Today, a patient moves through the doctor’s office, pharmacy, telehealth, social platforms and AI in a completely non-linear order. An HCP draws on the EHR, clinical AI, guidelines and colleagues simultaneously as they make a treatment decision.

Marketers must shift from planning static touchpoints to building dynamic systems capable of reading live signals and delivering practical help right when it is needed.

AI easily helps pharma produce more personalised messages at scale, but simply increasing the volume of messaging is not the answer. The real opportunity lies in understanding a customer's context well enough to provide exactly what they need – be it evidence, support, treatment guidance or a service – in the exact moment they need it.

Connecting capabilities for real growth

To deliver context-responsive engagement, everything needs to be connected. Across medical, clinical, access and commercial departments, teams routinely plan and execute separately. Intelligence gets trapped between functions, meaning an access change known to one team fails to trigger a response from another. That fragmentation is impossible to defend when customers are moving seamlessly between channels and services.

Brand leaders must urgently audit their internal structures and replace siloed planning with a unified operating model that connects strategy directly to execution.

If pharma wants to recognise context and respond to it, signals must travel seamlessly. By leveraging advanced data solutions and a connected platform approach, organisations can ensure intelligence moves fluidly across the business. When evidence, expertise and capabilities are united around the exact customer problem, brands transform fragmented data into a clear competitive advantage that drives sustainable growth.

To navigate this disruption and drive transformational growth, healthcare brands must adopt these immediate strategies:

• Unify intelligence: break down internal barriers between medical, commercial and access teams to create a single, shared view of customer signals.
• Optimise for real-time context: move beyond static journey mapping and utilise predictive data to deliver practical value exactly when the patient or HCP needs it most.
• Leverage connected platforms: deploy technology that connects your capabilities and automates workflows, ensuring your response to customer needs is coordinated, secure and deployed at scale.

The beautifully orchestrated PowerPoint journey is a relic of the past but this new era of marketing offers unprecedented opportunities for brands willing to adapt. By aligning around connected intelligence and context-responsive engagement, pharma brands can confidently navigate AI-driven disruption and secure their place as an indispensable partner in healthcare.

^{* Shapiro Ben David, S., Romano, R., Rahamim-Cohen, D. et al. AI driven decision support reduces antibiotic mismatches and inappropriate use in outpatient urinary tract infections. npj Digit. Med. 8, 61 (2025).}